BREAKING
Earnings Summary: A snapshot of Duke Energy’s Q4 2025 report 13 hours ago Fiserv (FISV) Earnings: 4Q25 Key Numbers 14 hours ago CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline 15 hours ago Chegg Q4 2025 Earnings Soar: New Strategy Stuns Market 1 day ago PAL Q4 2025 Earnings Explode: Mergers Pay Off Now 1 day ago Outdoor Holding Company Q3 2026 Earnings Soar 7% 1 day ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 1 day ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 1 day ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 2 days ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 2 days ago Earnings Summary: A snapshot of Duke Energy’s Q4 2025 report 13 hours ago Fiserv (FISV) Earnings: 4Q25 Key Numbers 14 hours ago CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline 15 hours ago Chegg Q4 2025 Earnings Soar: New Strategy Stuns Market 1 day ago PAL Q4 2025 Earnings Explode: Mergers Pay Off Now 1 day ago Outdoor Holding Company Q3 2026 Earnings Soar 7% 1 day ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 1 day ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 1 day ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 2 days ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 2 days ago
ADVERTISEMENT
Market News

Earnings Summary: Cardinal Health Q1 2026 revenue jumps 22%; raises guidance

Pharmaceuticals distributor Cardinal Health (NYSE: CAH) reported a sharp increase in revenue and adjusted earnings for the first quarter of fiscal 2026. The company also raised its full-year guidance. First-quarter revenue increased 22% year-over-year to $64 billion The Pharmaceutical and Specialty Solutions segment revenue increased 23%; Global Medical Products and Distribution revenue rose 2% Net […]

October 30, 2025 1 min read

Pharmaceuticals distributor Cardinal Health (NYSE: CAH) reported a sharp increase in revenue and adjusted earnings for the first quarter of fiscal 2026. The company also raised its full-year guidance.

  • First-quarter revenue increased 22% year-over-year to $64 billion
  • The Pharmaceutical and Specialty Solutions segment revenue increased 23%; Global Medical Products and Distribution revenue rose 2%
  • Net income increased to $450 million or $1.88 per share in Q1 from $416 million or $1.70 per share last year
  • On an adjusted basis, earnings were $2.55 per share in the September quarter, vs. $1.88 per share in Q1 2025
  • Operating earnings increased 18% from last year to $668 million in the first quarter; adj. operating earnings rose 37%
  • The management raised its fiscal year 2026 adjusted earnings guidance to $9.65-9.85 per share
  • The outlook for full-year adjusted free cash flow has been increased to the range of $3.0 to $3.5 billion
ADVERTISEMENT